A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma.

Brief description of study

You can participate in this study if you are diagnosed with advanced liver cancer. The purpose of this study is to determine the efficacy and safety of the combination of study drugs (Atezolizumab) and (bevacizumab). The study is also being done to learn more about how the study drugs are absorbed (taken up in the body), metabolized (broken-down by the body), distributed (circulated in the body), and eliminated (passed out of the body). The patients will be monitored and taken care of while on these medications during the entire study period.


Clinical Study Identifier: s22-00519
ClinicalTrials.gov Identifier: NCT04829383
Principal Investigator: Kristen Spencer.
Other Investigators: Cristian C Papazoglu Statescu, Lawrence P Leichman, Theresa Ryan, Daniel J Becker, Jennifer Wu, Marta Wioleta Wronska, Jennifer Chuy, Monica Rivera, Keriann M Scavone, Paul E. Oberstein, Nina Beri, Anastasiya Apanasyuk, Michael Shusterman, Rafael Winograd, Shun Yu, Mary Lynn R Nierodzik, Alexander A Hindenburg.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.